Core Insights - The company achieved a 12% full-year revenue growth despite a decline in U.S. injectable volumes for only the third time in 25 years [1] - Jeuveau captured a 14% market share through a 'beauty-first' strategy that focuses on cash-pay aesthetic practices rather than reimbursement models [1] - The company successfully piloted a new portfolio growth rebate program to incentivize accounts to consolidate toxin and filler spending with Evolus [1] Financial Performance - International revenue nearly doubled year-over-year, driven by a transition to a direct model in Germany and approaching double-digit market share in the U.K. [1] - A structural expense reset was executed in mid-2025 to align the organization for durable, profitable growth and meaningful operating leverage [1] Product and Market Strategy - The Evolysse HA filler footprint expanded to over 3,000 purchasing accounts, utilizing Cold-X Technology to meet consumer demand for natural-looking results [1] - The company maintained brand resilience through Evolus Rewards, an SMS-based loyalty program that has grown to over 1.4 million treated patients [1]